Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer.
Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer.
复制标题
肿瘤知情和肿瘤不知情循环肿瘤DNA在结直肠癌最小残留疾病评估中的临床应用。
DOI：
10.3390/cancers13184547
复制
发表时间：
2021-09-10
期刊：
影响因子：
5.2
通讯作者：
Hitchins M
中科院分区：
文献类型：
--
作者：
Gong J;Hendifar A;Gangi A;Zaghiyan K;Atkins K;Nasseri Y;Murrell Z;Figueiredo JC;Salvy S;Haile R;Hitchins M
循环肿瘤DNA或ctDNA是可以在结直肠癌患者血液中检测到的肿瘤DNA片段。测量血液中的ctDNA水平显示出提供重要信息的潜力，这些信息有助于结直肠癌患者的临床护理。例如，在已经通过手术切除的结肠癌患者中，测量血液中的ctDNA可以预测癌症复发的可能性，而在转移性结直肠癌患者中，测量ctDNA可以告知临床医生化疗是否在比目前可用的测试更早的时间点有效。在这篇综述中，我们讨论了正在进行的研究的结果，描述了在结直肠癌的所有阶段的ctDNA测量的效用。我们还讨论了ctDNA可能对结直肠癌管理产生最直接影响的各种临床情况。新出现的数据表明，循环肿瘤DNA（ctDNA）可以在非转移性和转移性环境中检测结直肠癌（CRC）特异性信号。随着多个平台的发展，包括肿瘤知情和肿瘤不可知的ctDNA检测及其检测微小残留疾病的挑衅性分析性能的证明，现在正在进行III期随机临床试验，以评估其在CRC管理模式中的作用。在这篇综述中，我们重点介绍了具有里程碑意义的研究，这些研究为正在进行的关于血浆ctDNA检测在切除的I-III期CRC和转移性CRC中的临床适用性的研究奠定了基础。我们讨论了ctDNA在常规临床实践中可能产生最直接影响的临床环境。这些包括ctDNA的潜力：（1）指导切除的I-III期CRC辅助治疗的监测和强化或去强化策略，（2）预测局部晚期直肠癌（包括全新辅助治疗（TNT））对新辅助治疗的治疗反应，以及（3）预测转移性疾病对全身和手术治疗的反应。最后，我们考虑临床变量，可以影响我们在临床上可靠地解释ctDNA动力学的能力。
Circulating tumor DNA, or ctDNA, are fragments of tumor DNA that can be detected in the blood of patients with colorectal cancer. Measuring ctDNA levels in the blood has shown the potential to provide important information that can be helpful in the clinical care of patients with colorectal cancer. For example, in patients with colon cancer that has been removed by surgery, measuring ctDNA in the blood can predict the likelihood of cancer recurrence, while in those with metastatic colorectal cancer, measuring ctDNA can inform the clinician whether chemotherapy is effective at earlier timepoints than currently available tests. In this review, we discuss the results from ongoing studies describing the utility of ctDNA measurements across all stages of colorectal cancer. We also discuss the various clinical scenarios that ctDNA may have the most immediate impact in colorectal cancer management. Emerging data suggest that circulating tumor DNA (ctDNA) can detect colorectal cancer (CRC)-specific signals across both non-metastatic and metastatic settings. With the development of multiple platforms, including tumor-informed and tumor-agnostic ctDNA assays and demonstration of their provocative analytic performance to detect minimal residual disease, there are now ongoing, phase III randomized clinical trials to evaluate their role in the management paradigm of CRC. In this review, we highlight landmark studies that have formed the basis for ongoing studies on the clinically applicability of plasma ctDNA assays in resected, stage I–III CRC and metastatic CRC. We discuss clinical settings by which ctDNA may have the most immediate impact in routine clinical practice. These include the potential for ctDNA to (1) guide surveillance and intensification or de-intensification strategies of adjuvant therapy in resected, stage I–III CRC, (2) predict treatment response to neoadjuvant therapy in locally advanced rectal cancer inclusive of total neoadjuvant therapy (TNT), and (3) predict response to systemic and surgical therapies in metastatic disease. We end by considering clinical variables that can influence our ability to reliably interpret ctDNA dynamics in the clinic.
登录
查看更多内容
DOI：
10.6004/jnccn.2018.0061
发表时间：
2018-07
期刊：
Journal of the National Comprehensive Cancer Network : JNCCN
影响因子：
--
作者：
Benson AB;Venook AP;Al-Hawary MM;Cederquist L;Chen YJ;Ciombor KK;Cohen S;Cooper HS;Deming D;Engstrom PF;Grem JL;Grothey A;Hochster HS;Hoffe S;Hunt S;Kamel A;Kirilcuk N;Krishnamurthi S;Messersmith WA;Meyerhardt J;Mulcahy MF;Murphy JD;Nurkin S;Saltz L;Sharma S;Shibata D;Skibber JM;Sofocleous CT;Stoffel EM;Stotsky-Himelfarb E;Willett CG;Wuthrick E;Gregory KM;Gurski L;Freedman-Cass DA
通讯作者：
Freedman-Cass DA
影响因子：
4.7
作者：
Cao, Hua;Liu, Xinyi;Xu, Ruilian
通讯作者：
Xu, Ruilian
影响因子：
3.1
作者：
Boysen, Anders K.;Pallisgaard, Niels;Spindler, Karen-Lise G.
通讯作者：
Spindler, Karen-Lise G.
影响因子：
--
作者：
Carpinetti, Paola;Donnard, Elisa;Camargo, Anamaria A.
通讯作者：
Camargo, Anamaria A.
影响因子：
24.5
作者：
Barault L;Amatu A;Siravegna G;Ponzetti A;Moran S;Cassingena A;Mussolin B;Falcomatà C;Binder AM;Cristiano C;Oddo D;Guarrera S;Cancelliere C;Bustreo S;Bencardino K;Maden S;Vanzati A;Zavattari P;Matullo G;Truini M;Grady WM;Racca P;Michels KB;Siena S;Esteller M;Bardelli A;Sartore-Bianchi A;Di Nicolantonio F
通讯作者：
Di Nicolantonio F